-
Capital, M&A & Industry Strategy2 months agoBiotech’s 2026 IPOs deliver broad gains through August
BIOCENTURY | DATA BYTEBIOTECH’S 2026 IPOS DELIVER BROAD GAINS THROUGH AUGUST18 of 21 are trading above their IPO price
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoBrainChild: Bringing CAR Ts directly to the brain
BIOCENTURY | EMERGING COMPANY PROFILEBRAINCHILD: BRINGING CAR TS DIRECTLY TO THE BRAINRepeat dosing into the CSF is designed to sidestep the toxicities that have limited CNS-directed...
-
Drug Discovery & Therapeutics2 months agoCloverleaf: Turning 5-FU’s overlooked RNA mechanism into a new payload
BIOCENTURY | EMERGING COMPANY PROFILECLOVERLEAF: TURNING 5-FU’S OVERLOOKED RNA MECHANISM INTO A NEW PAYLOADYale spinout lands a $33M pharma-backed seed round to develop antibody conjugates carrying...
-
Capital, M&A & Industry Strategy2 months agoGan & Lee’s first big cross-border deal aids Menarini push into obesity
BIOCENTURY | DEALSGAN & LEE’S FIRST BIG CROSS-BORDER DEAL AIDS MENARINI PUSH INTO OBESITYData for twice-monthly GLP-1R agonist were competitive vs. market leaders Zepbound and Wegovy
-
Regulatory Intelligence & Drug Approvals2 months agoSix first-in-class approvals in August
BIOCENTURY | DATA BYTESIX FIRST-IN-CLASS APPROVALS IN AUGUSTEarly September approvals include Ionis’ Zanvastro for Alexander disease, AZ’s Etcamah for breast cancer
-
Capital, M&A & Industry Strategy2 months agoSuperluminal’s $60M series B to drive first clinical study: Finance Report
BIOCENTURY | FINANCESUPERLUMINAL’S $60M SERIES B TO DRIVE FIRST CLINICAL STUDY: FINANCE REPORTPlus: Gene insertion company Typewriter launches with series A; Electra files for NASDAQ listing;...
-
Drug Discovery & Therapeutics2 months agoBeyond the genome: Regeneron’s Abecasis on scaling drug discovery with genetic data
BIOCENTURY | DISCOVERY & TRANSLATIONBEYOND THE GENOME: REGENERON’S ABECASIS ON SCALING DRUG DISCOVERY WITH GENETIC DATAThe BioCentury Show: Target discovery outpaces data size at the Regeneron...
-
Regulatory Intelligence & Drug Approvals2 months agoRemembering Peter Barton Hutt, an icon of FDA law
BIOCENTURY | POLITICS, POLICY & LAWREMEMBERING PETER BARTON HUTT, AN ICON OF FDA LAWHutt shaped FDA’s approach to the law in the 1970s, helped craft food...
-
Global Biotechnology & Pharmaceutical Markets2 months agoK2 Therapeutics: Spreading bets across range of Asia-sourced assets
BIOCENTURY | EMERGING COMPANY PROFILEK2 THERAPEUTICS: SPREADING BETS ACROSS RANGE OF ASIA-SOURCED ASSETSFormer Legend CEO Ying Huang looks to $250M series A while aiming to replicate...
-
Regulatory Intelligence & Drug Approvals2 months agoWill Overton be a heat shield or a conduit for political and ideological influence?
BIOCENTURY | EDITOR'S COMMENTARYWILL OVERTON BE A HEAT SHIELD OR A CONDUIT FOR POLITICAL AND IDEOLOGICAL INFLUENCE?The answer to that question will determine FDA’s future
Widespread atropine use fails to sway FDA advisors on Sydnexis data
At least 11 PDUFAs on FDA’s November docket
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
